



## HEALTHCARE, LIFE SCIENCES & PHARMACEUTICALS

## Guidance Document from the Medical Devices Coordination Group

In June 2022, at one of the annual meetings of the Employment, Social Policy, Health and Consumer Affairs ("EPSCO") Council, health ministers expressed their concerns regarding the legislative transition to Regulation (EU) No 2017/745 of the European Parliament and of the European Council of 5 April 2017 on medical devices ("MDR") and to Regulation 2017/746 of the European Parliament and of the European Council of 5 April 2017 on in vitro diagnostic medical devices ("IVDR").

Health ministers expressed their concerns regarding the legislative transition to the medical devices and in vitro diagnostic medical devices regulations.

As a result, the MDCG was asked to make an urgent proposal for solutions to assist in the legislative transition to the legal framework established by the regulations described above.

These regulations have imposed new obligations with only a short transition period. This is not compatible with the adjustment capacity of notified bodies and manufacturers to adapt their medical devices and in vitro devices in accordance with those obligations.

If not properly addressed, the difficulties identified could lead to disruption of the supply of devices for healthcare systems and patients. They could also hinder access to innovative medical devices.

Eduardo Nogueira Pinto Ricardo Rocha Rita Antunes da Cunha Healthcare, Life Sciences & Pharmaceuticals team

## The MDCG has drafted a guidance document to facilitate the implementation of the new regulatory requirements provided for in European legislation.

In this context, the MDCG has drafted a <u>guidance document</u> to facilitate the implementation of the new regulatory requirements provided for in European legislation. The document is subdivided into the following topics:

- i) Increased capacity for notified bodies
- ii) Access to the notified bodies
- iii) Increased preparation of manufacturers
- iv) Other actions to facilitate transition and/or prevent device shortages

The progress and impact of these measures will be assessed by the MDCG to ascertain the need for further action.

For additional background on the MDR and the IVDR, please see our earlier Informative Notes: (i) the Informative Notes of June 2021 and August 2022, both on the new regulation on medical devices, and the Informative Note of May 2022 on the new regulation applicable to in vitro diagnostic medical devices.

PLMJ COLAB ANGOLA – GUINEA-BISSAU – MOZAMBIQUE – PORTUGAL – SÃO TOMÉ AND PRÍNCIPE – TIMOR-LESTE

This document is intended for general distribution to clients and colleagues, and the information contained in it is provided as a general and abstract overview. It should not be used as a basis on which to make decisions and professional legal advice should be sought for specific cases. The contents of this document may not be reproduced, in whole or in part, without the express consent of the author. If you require any further information on this topic, please contact Eduardo Nogueira Pinto (eduardo.nogueirapinto@plmj.pt) or Ricardo Rocha (ricardo.rocha@plmj.pt).